Literature DB >> 11007955

Signaling angiogenesis via p42/p44 MAP kinase and hypoxia.

E Berra1, J Milanini, D E Richard, M Le Gall, F Viñals, E Gothié, D Roux, G Pagès, J Pouysségur.   

Abstract

Angiogenesis is associated with a number of pathological situations. In this study, we have focused our attention on the role of p42/p44 MAP (mitogen-activated protein) kinases and hypoxia in the control of angiogenesis. We demonstrate that p42/p44 MAP kinases play a pivotal role in angiogenesis by exerting a determinant action at three levels: i) persistent activation of p42/p44 MAP kinases abrogates apoptosis; ii) p42/p44 MAP kinase activity is critical for controlling proliferation and growth arrest of confluent endothelial cells; and iii) p42/p44 MAP kinases promote VEGF (vascular endothelial growth factor) expression by activating its transcription via recruitment of the AP-2/Sp1 (activator protein-2) complex on the proximal region (-88/-66) of the VEGF promoter and by direct phosphorylation of hypoxia-inducible factor 1 alpha (HIF-1 alpha). HIF-1 alpha plays a crucial role in the control of HIF-1 activity, which mediates hypoxia-induced VEGF expression. We show that oxygen-regulated HIF-1 alpha protein levels are not affected by intracellular localization (nucleus versus cytoplasm). Finally, we propose a model which suggests an autoregulatory feedback mechanism controlling HIF-1 alpha and therefore HIF-1-dependent gene expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007955     DOI: 10.1016/s0006-2952(00)00423-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  53 in total

1.  Matrix-Bound VEGF Mimetic Peptides: Design and Endothelial Cell Activation in Collagen Scaffolds.

Authors:  Tania R Chan; Patrick J Stahl; S Michael Yu
Journal:  Adv Funct Mater       Date:  2011-11-22       Impact factor: 18.808

2.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.

Authors:  Akulapalli Sudhakar; Pia Nyberg; Venkateshwar G Keshamouni; Arjuna P Mannam; Jian Li; Hikaru Sugimoto; Dominic Cosgrove; Raghu Kalluri
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

3.  The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.

Authors:  Daniel E Foxler; Katherine S Bridge; Victoria James; Thomas M Webb; Maureen Mee; Sybil C K Wong; Yunfeng Feng; Dumitru Constantin-Teodosiu; Thorgunnur Eyfjord Petursdottir; Johannes Bjornsson; Sigurdur Ingvarsson; Peter J Ratcliffe; Gregory D Longmore; Tyson V Sharp
Journal:  Nat Cell Biol       Date:  2012-01-29       Impact factor: 28.824

4.  Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide.

Authors:  Luca Domenico D'Andrea; Guido Iaccarino; Roberto Fattorusso; Daniela Sorriento; Concetta Carannante; Domenica Capasso; Bruno Trimarco; Carlo Pedone
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

5.  Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.

Authors:  Guo Wei; Ruchika Srinivasan; Carmen Z Cantemir-Stone; Sudarshana M Sharma; Ramasamy Santhanam; Michael Weinstein; Natarajan Muthusamy; Albert K Man; Robert G Oshima; Gustavo Leone; Michael C Ostrowski
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

Review 6.  Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy.

Authors:  Juan-Juan Wang; Meili Zhu; Yun-Zheng Le
Journal:  World J Diabetes       Date:  2015-06-10

7.  Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Authors:  Danielle A Murphy; Sosina Makonnen; Wiem Lassoued; Michael D Feldman; Christopher Carter; William M F Lee
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Authors:  Yu-Chen Cai; Yong Zou; Yan-Li Ye; Hong-Yi Sun; Quan-Guan Su; Zhi-Xin Wang; Zhao-Lei Zeng; Li-Jian Xian
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

9.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.

Authors:  Shaun W Jackson; Tomokazu Hoshi; Yan Wu; Xiaofeng Sun; Keiichi Enjyoji; Eva Cszimadia; Christian Sundberg; Simon C Robson
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

10.  VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma.

Authors:  Duoduo Wang; Qinjie Weng; Lei Zhang; Qiaojun He; Bo Yang
Journal:  Cell Mol Neurobiol       Date:  2008-12-02       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.